ReviewInternational journal of molecular sciences2021
The Role of Host Glycobiology and Gut Microbiota in Rotavirus and Norovirus Infection, an Update.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 31 citations in OpenAlex.
- SARS-CoV-2 Persistence and the Gut Microbiota: New Insights into Long COVID Pathogenesis.Viruses · 2026Review
- FUT2-mediated intestinal fucosylation: a master regulator of host-microbiota symbiosis in health and disease.Frontiers in microbiology · 2026Review
- Article
- Fucose dependent rotavirus and norovirus require fucosidase activity for optimal replication.Npj viruses · 2025Article
- CVID Enteropathy Associated With Chronic Norovirus Infection: Background, Clinical Features, and Therapeutic Aspects.Reviews in medical virology · 2025Review
- The Gut Microbiome in Enteric Viral Infections: Underlying Mechanisms and Therapeutic Approaches.Microorganisms · 2025Review
- Fecal gut microbiome alterations and its association with lactose intolerance in children with rotavirus infection-related diarrhea.European journal of pediatrics · 2025Article
- Non-Secretor Status Due toMicroorganisms · 2025Article
- Understanding neurotropic enteric viruses: routes of infection and mechanisms of attenuation.Cellular and molecular life sciences : CMLS · 2024Review
- Probiotic Functions in Fermented Foods: Anti-Viral, Immunomodulatory, and Anti-Cancer Benefits.Foods (Basel, Switzerland) · 2024Review
- Article
- Article
- Prevalence, Clinical Features, and Genotypes of Norovirus-Associated Diarrhea in Wuxi, China, 2013-2020.The American journal of tropical medicine and hygiene · 2024Article
- The gut microbiota contributes to the infection of bovine viral diarrhea virus in mice.Journal of virology · 2024Article
- Culture of Human Rotaviruses in Relevant Models Shows Differences in Culture-Adapted and Nonculture-Adapted Strains.International journal of molecular sciences · 2023Article
- Microbiota do not restrict rotavirus infection of colon.Journal of virology · 2023Article
- Therapeutic Approach Targeting Gut Microbiome in Gastrointestinal Infectious Diseases.International journal of molecular sciences · 2023Review
- Characterization of Sialic Acid-Independent Simian Rotavirus Mutants in Viral Infection and Pathogenesis.Journal of virology · 2023Article
- Unraveling the interplay between norovirus infection, gut microbiota, and novel antiviral approaches: a comprehensive review.Frontiers in microbiology · 2023Review
- Intestinal Norovirus Binding Patterns in Nonsecretor Individuals.Journal of virology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Rotavirus (RV) and norovirus (NoV) are the leading causes of acute gastroenteritis (AGE) worldwide. Several studies have demonstrated that histo-blood group antigens (HBGAs) have a role in NoV and RV infections since their presence on the gut epithelial surfaces is essential for the susceptibility to many NoV and RV genotypes. Polymorphisms in genes that code for enzymes required for HBGAs synthesis lead to secretor or non-secretor and Lewis positive or Lewis negative individuals. While secretor individuals appear to be more susceptible to RV infections, regarding NoVs infections, there are too many discrepancies that prevent the ability to draw conclusions. A second factor that influences enteric viral infections is the gut microbiota of the host. In vitro and animal studies have determined that the gut microbiota limits, but in some cases enhances enteric viral infection. The ways that microbiota can enhance NoV or RV infection include virion stabilization and promotion of virus attachment to host cells, whereas experiments with microbiota-depleted and germ-free animals point to immunoregulation as the mechanism by which the microbiota restrict infection. Human trials with live, attenuated RV vaccines and analysis of the microbiota in responder and non-responder individuals also allowed the identification of bacterial taxa linked to vaccine efficacy. As more information is gained on the complex relationships that are established between the host (glycobiology and immune system), the gut microbiota and intestinal viruses, new avenues will open for the development of novel anti-NoV and anti-RV therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.